Researchers identified a 3-biomarker immunoassay, measuring NNMT, LCP1, and NM23A, that successfully distinguishes healthy patients from those with renal cell carcinoma (RCC). If their results can be validated, physicians would have an unprecedented tool for the early detection and subsequent treatment of this silent and deadly disease.
